Background The KEYNOTE-966 study demonstrated that pembrolizumab combined with chemotherapy is more effective than chemotherapy alone as first-line treatment for patients with advanced biliary tract ...

Biliary tract cancers (BTC), including gallbladder cancer and intrahepatic and extrahepatic cholangiocarcinoma, account for approximately 3% of all digestive system tumors and are often associated ...

Biliary tract infections (BTI), often linked to structural abnormalities like bile duct stones, pose significant treatment challenges due to drug-resistant bacteria like Pseudomonas aeruginosa.

Tovecimig combined with paclitaxel showed a 17.1% response rate in biliary tract cancer, outperforming paclitaxel alone. The COMPANION-002 study reported lower progressive disease rates with tovecimig ...

In the treatment of newly diagnosed biliary tract cancer, the current standard of care involves chemotherapy in combination with immunotherapy, utilizing agents such as Imfinzi (durvalumab) or ...

The FDA has approved a new drug, zanidatamab, for adults with advanced biliary tract cancer, or BTC. Marketed under the brand name Ziihera, it is a first-of-a-kind treatment for patients with HER2 ...

Nov 20 (Reuters) - The U.S. Food and Drug Administration approved Jazz Pharmaceuticals' , opens new tab drug for the treatment of a type of biliary tract cancer, the company said on Wednesday.

The FDA granted accelerated approval to zanidatamab-hrii for treatment of adults with previously treated unresectable or metastatic HER2-positive biliary tract cancer. Zanidatamab-hrii (Ziihera ...

References: Jazz Pharmaceuticals announces US FDA approval of Ziihera ® (zanidatamab-hrii) for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3 ...

The FDA on Wednesday granted accelerated approval to zanidatamab (Ziihera), a bispecific antibody, for pretreated HER2-positive biliary tract cancer.. Approval stipulates use in unresectable or ...

Biliary tract cancer (BTC) encompasses a group of invasive adenocarcinomas characterized by significant heterogeneity that is not only related to the anatomic site of origin (gallbladder v ...